Project description
Easy treatment device for hard-to-heal wounds
Hard-to-heal wounds can cause pain and sometimes lead to amputation. This problem affects about 50 million people around the world, mainly the elderly. Caused by diabetes or obesity, these wounds may take many different pathological forms. The EU-funded Piomic project aims to support the go-to-market strategy for the wearable medical device developed to treat such difficult-to-heal wounds. It helps the healing process, producing a durable structural closure, reduces pain, and cures infections. It is portable and designed for patient self-management. This energy-based technology is easy-to-use and will support safe therapy and improve the patient's quality of life.
Objective
Due to an aging population with growing rates of obesity and diabetes, over 50M patients suffer from hard-to-heal wounds annually, which has created a severe cost burden to global healthcare systems.
Piomic Medical AG, a Swiss Med-Tech company founded in 2016, develops a medical device to promote wound healing processes in hard-to-heal wounds. The device matches market mega-trends for portability and patient self-management. The patient may benefit from a faster healing process, reduced pain and inflammation as well as an improved treatment outcome. Early traction allowed Piomic to conduct a first in human clinical trial to evaluate safety and efficacy of its product and engage CE certification under MDD regulation.
The management team of Piomic consists of professionals with interdisciplinary knowledge in science and engineering, paired up with experts in regulatory affairs, life science and product development. We believe life shouldn't be defined by a medical condition. By developing a therapy which is safe and effective we hope to set a better future for everyone in need.
The feasibility study aims to validate the commercial feasibility of Piomic with target market segments and key stakeholders. We will strengthen our financial planning and IP protection strategy necessary to improve our service and refine our go-to-market strategy. We will also specify product features needed for a fully commercialized solution upgraded to TRL 9, after the SME Instrument Phase 2.
With a Total Addressable Market of €19.3 billion, we plan to reach €35m revenues by 2024 with 90+ FTEs employed.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
8004 ZURICH
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.